Ltd. Kck Sells 223,991 Shares of NeuroPace, Inc. (NASDAQ:NPCE) Stock

NeuroPace, Inc. (NASDAQ:NPCE) major shareholder Ltd. Kck sold 223,991 shares of the firm’s stock in a transaction on Friday, October 25th. The shares were sold at an average price of $5.45, for a total transaction of $1,220,750.95. Following the sale, the insider now owns 5,270,845 shares in the company, valued at approximately $28,726,105.25. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Ltd. Kck also recently made the following trade(s):

• On Wednesday, October 23rd, Ltd. Kck sold 147 shares of NeuroPace stock. The shares were sold at an average price of $6.02, for a total value of $884.94.
• On Monday, October 21st, Ltd. Kck sold 3,720 shares of NeuroPace stock. The stock was sold at an average price of $6.10, for a total value of $22,692.00.
• On Friday, October 18th, Ltd. Kck sold 4,878 shares of NeuroPace stock. The shares were sold at an average price of $6.29, for a total value of $30,682.62.
• On Wednesday, October 16th, Ltd. Kck sold 6,900 shares of NeuroPace stock. The stock was sold at an average price of $6.57, for a total value of $45,333.00.
• On Monday, October 14th, Ltd. Kck sold 4,031 shares of NeuroPace stock. The stock was sold at an average price of $6.54, for a total transaction of $26,362.74.
• On Friday, October 11th, Ltd. Kck sold 2,572 shares of NeuroPace stock. The shares were sold at an average price of $6.35, for a total transaction of $16,332.20.
• On Wednesday, October 9th, Ltd. Kck sold 3,123 shares of NeuroPace stock. The stock was sold at an average price of $6.10, for a total transaction of $19,050.30.
• On Monday, October 7th, Ltd. Kck sold 4,910 shares of NeuroPace stock. The stock was sold at an average price of $6.66, for a total value of $32,700.60.
• On Thursday, October 3rd, Ltd. Kck sold 3,318 shares of NeuroPace stock. The shares were sold at an average price of $6.97, for a total value of $23,126.46.

NeuroPace Stock Performance

Shares of NPCE stock opened at $6.49 on Wednesday. The firm has a market capitalization of $189.51 million, a price-to-earnings ratio of -5.95 and a beta of 1.78. The stock has a fifty day moving average of $6.94 and a 200 day moving average of $7.95. NeuroPace, Inc. has a 52 week low of $5.45 and a 52 week high of $18.15. The company has a quick ratio of 5.47, a current ratio of 6.37 and a debt-to-equity ratio of 5.97.

NeuroPace (NASDAQ:NPCE) last posted its earnings results on Tuesday, August 13th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.03. NeuroPace had a negative net margin of 41.63% and a negative return on equity of 195.26%. The firm had revenue of $19.26 million during the quarter, compared to analysts’ expectations of $18.30 million. During the same period last year, the company posted ($0.36) EPS. The company’s quarterly revenue was up 16.6% compared to the same quarter last year. As a group, research analysts expect that NeuroPace, Inc. will post -1.08 earnings per share for the current year.

Institutional Trading of NeuroPace

Several large investors have recently bought and sold shares of the company. Financial Advocates Investment Management raised its position in shares of NeuroPace by 20.0% in the 3rd quarter. Financial Advocates Investment Management now owns 18,000 shares of the company’s stock worth $125,000 after acquiring an additional 3,000 shares in the last quarter. Millennium Management LLC grew its stake in NeuroPace by 13.3% in the second quarter. Millennium Management LLC now owns 686,037 shares of the company’s stock worth $5,186,000 after purchasing an additional 80,324 shares during the period. XTX Topco Ltd raised its holdings in NeuroPace by 56.1% in the second quarter. XTX Topco Ltd now owns 24,055 shares of the company’s stock worth $182,000 after purchasing an additional 8,643 shares in the last quarter. Acadian Asset Management LLC lifted its position in NeuroPace by 46.0% during the second quarter. Acadian Asset Management LLC now owns 68,918 shares of the company’s stock valued at $520,000 after buying an additional 21,703 shares during the period. Finally, Rhumbline Advisers bought a new stake in shares of NeuroPace during the 2nd quarter valued at $111,000. 78.83% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

NPCE has been the subject of several recent research reports. Morgan Stanley lowered their price objective on NeuroPace from $9.50 to $8.00 and set an “equal weight” rating for the company in a research report on Monday, July 15th. Wells Fargo & Company dropped their price target on shares of NeuroPace from $20.00 to $15.00 and set an “overweight” rating for the company in a research report on Wednesday, August 14th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $18.00 price objective on shares of NeuroPace in a research report on Wednesday, August 14th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $14.00.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.